NCT05962450 2024-01-16
Adoptive Autologous iNKT Cells for the Treatment of Progressed Hepatocellular Carcinoma Continuing on PD-1 Inhibitor Therapy
Beijing YouAn Hospital
Phase 2 Unknown
Clinical Trials
8 trialsNCT05134532 2023-04-26
HCC
CHA University
Phase 2 Unknown
NCT05811481 2023-04-13
ROSE
First Affiliated Hospital, Sun Yat-Sen University
Unknown
NCT05048017 2023-03-29
Regorafenib Combined With PD-1 Inhibitor Therapy for Second-line Treatment of Hepatocellular Carcinoma
Peking Union Medical College Hospital
Phase 2 Unknown
NCT03475953 2023-03-03
REGOMUNE
Institut Bergonié
Phase 1/2 Unknown
NCT05557656 2022-12-29
A Real World Study of Regogfinib in HCC
Zhongda Hospital
Unknown
NCT04718909 2022-11-10
REGSIN
Second Affiliated Hospital of Guangzhou Medical University
Phase 2 Unknown
NCT05233358 2022-02-10
HAIC Combined With Second-line "Target Immunity" for HCC With TACE Standard Treatment Low Response or Failure
The Central Hospital of Lishui City
Phase NA Unknown